Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in:

Open Access 01-12-2024 | Review

Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications

Authors: Hua-Qi Si, Peng Wang, Fei Long, Wei Zhong, Yuan-Dong Meng, Yuan Rong, Xiang-Yu Meng, Fu-Bing Wang

Published in: Molecular Cancer | Issue 1/2024

Login to get access

Abstract

Liquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the current landscape of cancer diagnostics and treatment. However, the existing methods for cfDNA-based liquid biopsies for cancer have certain limitations, such as fragment interruption and GC bias, which are likely to be resolved by the emerging Oxford Nanopore Technologies (ONT), characterized by long read-length, fast read-times, high throughput, and polymerase chain reaction-free. In this review, we summarized the current literatures regarding the feasibility and applications of cfDNA-based liquid biopsies using ONT for cancer management, a possible game-changer that we believe is promising in detecting multimodal biomarkers and can be applied in a wide range of oncology utilities including early screening, diagnosis, and treatment monitoring.

Graphical abstract

Literature
1.
Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.PubMedCrossRef
2.
Li S, et al. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer. 2021;148(11):2640–51.PubMedCrossRef
3.
Heitzer E, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88.PubMedCrossRef
4.
Luo H, et al. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends Mol Med. 2021;27(5):482–500.PubMedCrossRef
5.
Lo YMD. et al. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021;372(6538):eaaw3616.
6.
Gaitsch H, Franklin RJM, Reich DS. Cell-free DNA-based liquid biopsies in neurology. Brain. 2023;146(5):1758–74.PubMedCrossRef
7.
Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer–a survey. Biochim Biophys Acta. 2007;1775(1):181–232.PubMed
8.
Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–59.PubMedCrossRef
9.
Shen SY, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563(7732):579–83.PubMedCrossRef
10.
Pascual J, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750–68.PubMedCrossRef
11.
12.
Santis G, et al. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS ONE. 2011;6(9):e25191.PubMedPubMedCentralCrossRef
13.
Sorenson GD, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3(1):67–71.PubMed
14.
Sorber L, et al. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2017;107:100–7.PubMedCrossRef
15.
van Dijk EL, et al. Ten years of next-generation sequencing technology. Trends Genet. 2014;30(9):418–26.PubMedCrossRef
16.
Yu SCY. et al. Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. Proc Natl Acad Sci USA. 2021;118(50):e2114937118.
17.
Clarke J, et al. Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol. 2009;4(4):265–70.PubMedCrossRef
18.
19.
Dorey A, Howorka S. Nanopore DNA sequencing technologies and their applications towards single-molecule proteomics. Nat Chem. 2024;16(3):314–34.PubMedCrossRef
20.
Katsman E, et al. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing. Genome Biol. 2022;23(1):158.PubMedPubMedCentralCrossRef
21.
van der Pol Y, et al. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing. EMBO Mol Med. 2023;15(12):e17282.PubMedPubMedCentralCrossRef
22.
Yu SCY, et al. Comparison of single molecule, real-time sequencing and nanopore sequencing for analysis of the size, end-motif, and tissue-of-origin of long cell-free DNA in plasma. Clin Chem. 2023;69(2):168–79.PubMedCrossRef
23.
Hosny G, Farahat N, Hainaut P. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin’s lymphoma. Cancer Lett. 2009;275(2):234–9.PubMedCrossRef
24.
Hosny G, et al. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Lett. 2008;264(2):201–8.PubMedCrossRef
25.
Dobrzycka B, et al. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Ann Oncol. 2011;22(5):1133–40.PubMedCrossRef
26.
Castellanos-Rizaldos E, et al. Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment. Clin Chem. 2012;58(7):1130–8.PubMedPubMedCentralCrossRef
27.
Zhang L, et al. Emerging digital PCR technology in precision medicine. Biosens Bioelectron. 2022;211:114344.PubMedCrossRef
28.
29.
Song P, et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022;6(3):232–45.PubMedPubMedCentralCrossRef
30.
31.
32.
33.
34.
Zhang K, et al. Circulating cell-free DNA-based multi-cancer early detection. Trends Cancer. 2024;10(2):161–74.PubMedCrossRef
35.
Forshew T, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68.PubMedCrossRef
36.
Tie J, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715–22.PubMedPubMedCentralCrossRef
37.
38.
Rothé F, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014;25(10):1959–65.PubMedCrossRef
39.
Moldovan N, et al. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis. Cell Rep Med. 2024;5(1):101349.PubMedCrossRef
40.
Taiwo O, et al. Methylome analysis using MeDIP-seq with low DNA concentrations. Nat Protoc. 2012;7(4):617–36.PubMedCrossRef
41.
42.
43.
Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res. 2010;38(2):391–9.PubMedCrossRef
44.
45.
46.
Walker B, et al. A pore-forming protein with a metal-actuated switch. Protein Eng. 1994;7(5):655–62.PubMedCrossRef
47.
Ying YL, et al. Nanopore-based technologies beyond DNA sequencing. Nat Nanotechnol. 2022;17(11):1136–46.PubMedCrossRef
48.
49.
Zheng P, et al. Nanopore sequencing technology and its applications. MedComm (2020). 2023;4(4):316.CrossRef
50.
Petersen LM. et al. Third-generation sequencing in the clinical laboratory: exploring the advantages and challenges of nanopore sequencing. J Clin Microbiol. 2019;58(1):e01315–19.
51.
52.
53.
Rhoads A, Au KF. PacBio Sequencing and Its Applications. Genom Proteom Bioinform. 2015;13(5):278–89.CrossRef
54.
Ardui S, et al. Single molecule real-time (SMRT) sequencing comes of age: applications and utilities for medical diagnostics. Nucleic Acids Res. 2018;46(5):2159–68.PubMedPubMedCentralCrossRef
55.
56.
57.
58.
59.
Helmersen K, Aamot HV. DNA extraction of microbial DNA directly from infected tissue: an optimized protocol for use in nanopore sequencing. Sci Rep. 2020;10(1):2985.PubMedPubMedCentralCrossRef
60.
Huang YT, Liu PY, Shih PW. Homopolish: a method for the removal of systematic errors in nanopore sequencing by homologous polishing. Genome Biol. 2021;22(1):95.PubMedPubMedCentralCrossRef
61.
62.
Nawroz H, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2(9):1035–7.PubMedCrossRef
63.
Lo YM, et al. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet. 1998;351(9112):1329–30.PubMedCrossRef
64.
Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858–73.PubMedCrossRef
65.
Stadler JC, et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 2022;82(3):349–58.PubMedCrossRef
66.
67.
Anagnostou V, Velculescu VE. Pushing the boundaries of liquid biopsies for early precision intervention. Cancer Discov. 2024;14(4):615–9.PubMedCrossRef
68.
Martignano F, et al. Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. Mol Cancer. 2021;20(1):32.PubMedPubMedCentralCrossRef
69.
70.
Afflerbach AK, et al. Classification of brain tumors by nanopore sequencing of cell-free DNA from cerebrospinal fluid. Clin Chem. 2024;70(1):250–60.PubMedCrossRef
71.
Bruzek AK, et al. Electronic DNA analysis of CSF cell-free tumor DNA to quantify multi-gene molecular response in pediatric high-grade glioma. Clin Cancer Res. 2020;26(23):6266–76.PubMedPubMedCentralCrossRef
72.
73.
Burck N, et al. Nanopore identification of single nucleotide mutations in circulating tumor DNA by multiplexed ligation. Clin Chem. 2021;67(5):753–62.PubMedCrossRef
74.
Sol N, et al. Glioblastoma, IDH-wildtype with primarily leptomeningeal localization diagnosed by nanopore sequencing of cell-free DNA from cerebrospinal fluid. Acta Neuropathol. 2024;148(1):35.PubMedPubMedCentralCrossRef
75.
Sampathi S, et al. Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia. Front Oncol. 2022;12:958673.PubMedPubMedCentralCrossRef
76.
77.
78.
79.
Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483–9.PubMedCrossRef
80.
van Belzen I, et al. Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology. NPJ Precis Oncol. 2021;5(1):15.PubMedPubMedCentralCrossRef
81.
Akkhasutthikun P, et al. Tissue and plasma-based highly sensitive blocker displacement amplicon nanopore sequencing for EGFR mutations in lung cancer. Cancer Res Treat. 2024;56(2):455–63.PubMedCrossRef
82.
83.
84.
Lang J, et al. Nano2NGS-Muta: a framework for converting nanopore sequencing data to NGS-liked sequencing data for hotspot mutation detection. NAR Genom Bioinform. 2022;4(2):lqa033.CrossRef
85.
86.
87.
Ho SS, Urban AE, Mills RE. Structural variation in the sequencing era. Nat Rev Genet. 2020;21(3):171–89.PubMedCrossRef
88.
89.
90.
Chan KC, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A. 2013;110(47):18761–8.PubMedPubMedCentralCrossRef
91.
92.
Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol. 2013;754:31–56.PubMedCrossRef
93.
Moss J, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068.PubMedPubMedCentralCrossRef
94.
Sun K, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503–12.PubMedPubMedCentralCrossRef
95.
96.
97.
Im YR, et al. Next-generation liquid biopsies: embracing data science in oncology. Trends Cancer. 2021;7(4):283–92.PubMedCrossRef
98.
99.
100.
van der Vaart M, Pretorius PJ. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta. 2008;395(1–2):186.PubMedCrossRef
101.
102.
Hou Y, Meng XY, Zhou X. Systematically evaluating cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection via integrating multiple fragmentation patterns. Adv Sci (Weinh). 2024;11(30):e2308243.PubMedCrossRef
103.
Sun K, et al. Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Res. 2019;29(3):418–27.PubMedPubMedCentralCrossRef
104.
Zill OA, et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res. 2018;24(15):3528–38.PubMedCrossRef
105.
Yang J, et al. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Rev Clin Oncol. 2023;20(4):211–28.PubMedCrossRef
106.
Rostami A, et al. Senescence, necrosis, and apoptosis govern circulating cell-free DNA release kinetics. Cell Rep. 2020;31(13):107830.PubMedCrossRef
107.
Sprang M, Paret C, Faber J. CpG-islands as markers for liquid biopsies of cancer patients. Cells. 2020;9(8):1820.
108.
109.
Pagès-Gallego M, de Ridder J. Comprehensive benchmark and architectural analysis of deep learning models for nanopore sequencing basecalling. Genome Biol. 2023;24(1):71.PubMedPubMedCentralCrossRef
110.
Moser T, et al. Bridging biological cfDNA features and machine learning approaches. Trends Genet. 2023;39(4):285–307.PubMedCrossRef
111.
112.
Lin B, Hui J, Mao H. Nanopore technology and its applications in gene sequencing. Biosensors (Basel). 2021;11(7):214.
113.
Xie S, et al. Applications and potentials of nanopore sequencing in the (epi)genome and (epi)transcriptome era. Innovation (Camb). 2021;2(4):100153.PubMed
114.
Wan YK, et al. Beyond sequencing: machine learning algorithms extract biology hidden in Nanopore signal data. Trends Genet. 2022;38(3):246–57.PubMedCrossRef
115.
116.
117.
Xu Y. et al. Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season. Euro Surveill. 2021;26(27):2000004.
118.
Fukuda Y, et al. Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus. Vaccine. 2024;42(11):2927–32.PubMedCrossRef
119.
Thijssen R, et al. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022;140(20):2127–41.PubMedPubMedCentralCrossRef
120.
Cortés-López M, et al. Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell Stem Cell. 2023;30(9):1262-1281.e8.PubMedPubMedCentralCrossRef
121.
122.
123.
Abbosh C, et al. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer. Trends Cancer. 2024;10(7):643–54.PubMedCrossRef
Metadata
Title
Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications
Authors
Hua-Qi Si
Peng Wang
Fei Long
Wei Zhong
Yuan-Dong Meng
Yuan Rong
Xiang-Yu Meng
Fu-Bing Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2024
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-024-02178-6

Other articles of this Issue 1/2024

Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway

The Technical University of Munich Cancer Center - elevating cancer treatment through science

Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma

The therapeutically actionable long non-coding RNA ‘T-RECS’ is essential to cancer cells’ survival in NRAS/MAPK-driven melanoma

Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance

Joint single-cell genetic and transcriptomic analysis reveal pre-malignant SCP-like subclones in human neuroblastoma

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits